CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
about
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune ResponseFoxp3+ regulatory T cells are required for recovery from severe sepsisHarnessing the Microbiome to Enhance Cancer ImmunotherapyOrchestration of angiogenesis by immune cellsNeutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-AnalysisThe Relationship between Obesity, Prostate Tumor Infiltrating Lymphocytes and Macrophages, and Biochemical FailureProstate cancer and inflammation: the evidence.A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma.Transcriptional regulation of FOXP3 requires integrated activation of both promoter and CNS regions in tumor-induced CD8+ Treg cells.Exacerbation of corneal scarring in HSV-1 gK-immunized mice correlates with elevation of CD8+CD25+ T cells in corneas of ocularly infected mice.CD8+ Tregs in lupus, autoimmunity, and beyond.The future potential for cocaine vaccines.Osteoclast activated FoxP3+ CD8+ T-cells suppress bone resorption in vitro.The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosisHuman prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadeCD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.Prostate cancer as a model for tumour immunotherapy.TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.Augmenting antitumor immune responses with epigenetic modifying agents.Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies.Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 TherapyIpilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma.The PCa Tumor Microenvironment.Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cellsProstate cancer immunotherapy.A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells.Interleukin-35 administration counteracts established murine type 1 diabetes--possible involvement of regulatory T cells.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment.Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasiaCharacterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells.Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence
P2860
Q26740601-2EBC0618-FC0D-4EDF-B8F3-A5941443B5D8Q26744527-FCF932A1-3010-43A8-B5E9-D90ACC4BFEA6Q27317316-68FB101B-8F70-4E05-825B-8393FFD29F99Q28088598-2FB94A1A-9272-41D7-8353-DA74418D7BF7Q28389236-66E3416E-B763-455C-8D8A-471504EAFDAEQ28552296-4537BE2E-A815-4484-9961-9BC2379E8A89Q28553364-BDDDC163-15F1-4A62-B595-0D9088BE85DBQ33642321-26F74778-0C39-42DB-AB1D-2C802BB36EAAQ33685646-B8B5B163-6733-4115-86D6-13FA2878DC1DQ33686415-7ABA0070-E0B5-4F04-83DB-ACF9862E52FDQ33695351-86F39DBB-951D-4551-B281-E177A038FB24Q33889097-B2325B46-A292-4599-91EF-1867755C6E3EQ34132804-9DB6205E-A061-43EC-9974-8F1CFC0E3BE2Q34305347-FB5466BA-4AE9-415A-8A52-710A1A127C5EQ34315871-E00741B6-3191-4B70-898F-DB4956422FCCQ34478019-89CBEDFF-D6E5-47E2-AD35-00AAA2131CD9Q34612943-74F666D5-B8D3-44FB-9E86-39A7F107FEBFQ34645401-A1F16C2C-0831-4444-AF84-217FFB8DEF67Q34725101-F271A0DE-6FAB-4017-9F7E-D40A51334A94Q34856875-58544B6B-DF2D-4E9B-8B1F-63F232CEFAE3Q34880391-46EB78BF-ECC8-4F31-A0DC-416B5226D90BQ35048054-C5469B45-05FB-4AAB-8373-8AA550595E9CQ35285757-157713BA-B01A-4A8C-84AB-17ECDF11DD55Q35426986-6D34D8CD-7316-4F54-A81C-FC1A4ADACED8Q35567212-184A13D9-A5F9-4793-8DD3-5C3317247E93Q35570420-8E5E15F8-CC80-4542-AA73-709C072702C4Q35603143-9F08DEB6-F2A7-45B9-A836-5A9647A05EF7Q35644193-83F6E911-3E9B-4831-B0DB-953178C37F49Q35688425-978C0DA8-3638-4FB7-9B3D-B10B611A866DQ35864012-C022D437-9F4F-415E-AC76-0DA55E9F0A78Q35902052-4FB767EE-7E7D-4994-AE7C-DDB6B42FE751Q35980893-739CA56F-8733-4748-A656-CDDC2CF15BE5Q36015241-ECDC91A0-4B7F-4080-BF5B-C74BCD73B18FQ36055096-1F8D604F-D3C8-4C4E-8B3B-E1F2A5AE5EE5Q36085104-92923091-7B7C-4622-96E4-4A4DD66BCDF1Q36172036-7CDDA1CF-E5C6-4892-A724-069F289563F6Q36413093-57AA21FC-63B6-4895-9B13-225420C93DC1Q36456469-B2091207-9757-452B-83C0-033E63527C7DQ36602010-B528878F-89A9-40EA-8194-5107094AFEBAQ36625669-8C9CDDCB-94AB-42C0-8F49-1515BCD6399B
P2860
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@ast
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@en
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@nl
type
label
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@ast
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@en
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@nl
prefLabel
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@ast
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@en
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@nl
P2093
P1476
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
@en
P2093
Guangyong Peng
Helen Y Wang
Lloyd J Old
Rong-Fu Wang
Thomas M Wheeler
Timothy C Thompson
Weiyi Peng
Yoshihiro Miyahara
Yukiko Kiniwa
P304
P356
10.1158/1078-0432.CCR-07-0842
P407
P577
2007-12-01T00:00:00Z